ALK Inhibitor Sequencing in NSCLC 

David Spigel, MD; Tony Mok, MD; and Alice Shaw MD, PhD, outline sequencing of therapies in ALK- or ROS1-positive non-small cell lung cancer and how identifying resistance mutations can guide sequencing of ALK inhibitors through multiple relapses.